Stock Quote
Amylin Pharmaceuticals, Inc. (AMLN.O) (Nasdaq)
$13.80
1:00pm EST
-0.79%
$13.91
$13.49
2,030,929
$14.00
$13.25
$15.69
$5.92
1.66
1,686,285
AMLN.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Costa, Paulo | Chairman of the Board | -- |
| Bradbury, Daniel | President, Chief Executive Officer, Director | 4,059,280 |
| Foletta, Mark | Chief Financial Officer, Senior Vice President - Finance | 1,252,960 |
Profile
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide)... Full Description
Company Address
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
Suite 110
San Diego CA 92121
P: +1858.5522200
F: +1858.5522212
9360 Towne Centre Drive
Suite 110
San Diego CA 92121
P: +1858.5522200
F: +1858.5522212
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Pfizer Inc. | $18.25 | -0.34 |
| GlaxoSmithKline plc | £1,279.00 | +7.00 |
| Merck & Co., Inc. | $36.29 | -0.28 |
| AMLN.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.96 |
| P/S(TTM) | 2.41 | 29.74 |
| ROI(TTM) | -17.53 | 2.44 |
| ROE(TTM) | -52.93 | 3.72 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.28 |
| EPS Est. (Current Year) | -1.20 |
| Total Revenue | $211.24M |
| Net Income | $-26.66M |
| EPS | $-0.19 |
